Document is current
Any future updates will be listed below
-
Authors
Valo, Erkka https://orcid.org/0000-0003-0672-554X
Richmond, Anne
Mutter, Stefan https://orcid.org/0000-0002-8293-6982
Dahlström, Emma H. https://orcid.org/0000-0003-1271-8696
Campbell, Archie https://orcid.org/0000-0003-0198-5078
Porteous, David J. https://orcid.org/0000-0003-1249-6106
Wilson, James F. https://orcid.org/0000-0001-5751-9178
,
Mutter, Stefan
Groop, Per-Henrik https://orcid.org/0000-0003-4055-6954
Hayward, Caroline https://orcid.org/0000-0002-9405-9550
Sandholm, Niina https://orcid.org/0000-0003-4322-6942
- License Information
-
More Information
Article History
Received: 4 January 2024
Accepted: 27 November 2024
First Online: 2 January 2025
Competing interests
: P-H G has served on advisory boards for AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Cebix, Eli Lilly, Janssen, Medscape, MSD, Mundipharma, Nestlé, Novartis, Novo Nordisk, Sanofi, and has received lecture honoraria from Astellas, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Medscape, Menarini, MSD, Mundipharma, Novartis, Novo Nordisk PeerVoice Sanofi, and Sciarc. P-H G has also received investigator-initiated grants from Eli Lilly and Roche. S M received lecture honoraria from Encore Medical Education. All other authors declare no competing interests.
